Shiv O’neill Buys 3,998 Shares of Elanco Animal Health (NYSE:ELAN) Stock

Elanco Animal Health Incorporated (NYSE:ELAN) insider Shiv O’neill purchased 3,998 shares of Elanco Animal Health stock in a transaction that occurred on Tuesday, August 18th. The stock was purchased at an average price of $23.58 per share, with a total value of $94,272.84. Following the transaction, the insider owned 87,832 shares in the company, valued at $2,071,078.56. This represents a 4.77% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Elanco Animal Health Price Performance

ELAN opened at $24.47 on Thursday. The firm has a market capitalization of $12.22 billion, a P/E ratio of -59.67, a PEG ratio of 1.42 and a beta of 1.67. The stock has a fifty day moving average of $24.57 and a 200-day moving average of $24.01. The company has a quick ratio of 1.10, a current ratio of 2.05 and a debt-to-equity ratio of 0.58. Elanco Animal Health Incorporated has a 12-month low of $17.11 and a 12-month high of $27.98.

Elanco Animal Health (NYSE:ELAN) last issued its quarterly earnings results on Wednesday, August 5th. The company reported $0.34 earnings per share for the quarter, beating analysts’ consensus estimates of $0.27 by $0.07. The business had revenue of $1.37 billion for the quarter, compared to the consensus estimate of $1.31 billion. Elanco Animal Health had a positive return on equity of 8.13% and a negative net margin of 3.96%.Elanco Animal Health’s revenue for the quarter was up 10.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.26 earnings per share. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. Equities analysts forecast that Elanco Animal Health Incorporated will post 1.12 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms recently issued reports on ELAN. TD Cowen upped their price objective on shares of Elanco Animal Health from $31.00 to $32.00 and gave the stock a “buy” rating in a report on Thursday, June 18th. Morgan Stanley lifted their price objective on Elanco Animal Health from $23.00 to $26.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 22nd. JPMorgan Chase & Co. boosted their price objective on Elanco Animal Health from $28.00 to $30.00 and gave the stock an “overweight” rating in a research report on Thursday, May 7th. Citigroup upped their price target on Elanco Animal Health from $30.00 to $31.00 and gave the stock a “buy” rating in a report on Thursday, May 7th. Finally, Wall Street Zen downgraded shares of Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a research note on Sunday, May 24th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $29.09.

Institutional Investors Weigh In On Elanco Animal Health

Several large investors have recently modified their holdings of ELAN. Peak Retirement Planning Inc. acquired a new stake in shares of Elanco Animal Health in the 4th quarter valued at approximately $2,756,000. Norges Bank acquired a new position in Elanco Animal Health during the fourth quarter worth $32,415,000. Geneos Wealth Management Inc. raised its position in Elanco Animal Health by 3,358.1% during the first quarter. Geneos Wealth Management Inc. now owns 202,747 shares of the company’s stock worth $4,852,000 after acquiring an additional 196,884 shares in the last quarter. Allspring Global Investments Holdings LLC bought a new stake in Elanco Animal Health during the first quarter worth $66,390,000. Finally, OP Asset Management Ltd acquired a new stake in Elanco Animal Health in the first quarter valued at $8,171,000. 97.48% of the stock is currently owned by institutional investors.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.